

6. Literatur

- [1] M. Linnemann, M. Kühl. *Biochemie für Mediziner* 4. Auflage. **1995**, 451-453.
- [2] D. P. Berger, R. Engelhardt, R. Mertelsmann. *Das rote Buch Hämatologie und Internistische Onkologie* 2. Auflage. **2002**, 9-10.
- [3] E. Oberdisse, E. Hackenthal, K. Kuschinsky. *Pharmakologie und Toxikologie* Springer Verlag **1997**, 685-686.
- [4] D. P. Berger, R. Engelhardt, R. Mertelsmann. *Das rote Buch Hämatologie und Internistische Onkologie* 2. Auflage. **2002**, 47-48.
- [5] K. Burdzy, P. G. Munder, H. Fischer, O. Westphal. Steigerung der Phagozytose von Peritonealmakrophagen durch Lysolecithin. *Z Naturforsch* **1964**, 196, 1118-1120.
- [6] W. Hoppe, W. Lohmann, H. Markl und H. Ziegler. *Biophysik*, **1982**, Springer Verlag, Berlin, Heidelberg
- [7] R. L. Bell, P. W. Magierus. Thrombin-induced hydrolysis of phosphatidylinositol in human platelets. *J. Biol. Chem.* **1980**, 255, 1790- 1792.
- [8] H. Eibl, P. Wolley. A general synthesis method for enantiomerically pure ester and ether lysophospholipids. *Chem. Phys Lipids* **1988**, 47, 63-68.
- [9] H. Eibl, P. Wolley. Synthesis of enantiomerically pure glyceryl esters and ethers: I Methods employing the precursor 1,2-isopropylidene-D-manitol. *Chem. Phys Lipids* **1986**, 41, 53-63.
- [10] H. Eibl, P. Wolley. Synthesis of enantiomerically pure glyceryl esters and ethers: II Methods employing the precursor 1,2-isopropylidene-D-manitol. *Chem. Phys Lipids* **1988**, 47, 47-63.
- [11] Übersicht: H. Eibl. Phospholipide als funktionelle Bausteine biologischer Membranen. *Angew. Chem.* **1984**, 96, 247-262.
- [12] C. Unger, H. Eibl. Arzneimittelentwicklung aus Phospholipiden. *Onkologie* **2001**, 24, 18-23.
- [13] A. Wiese, T. Wieder, M. Mickleit, S. Reinöhl, C. Geilen, U. Seydel, W. Reutter. Structure-dependent effect of glucose-containing analogs of platelet activating factor on membrane integrity. *Biol. Chem.* **2000**, 381, 135-144.
- [14] J. Benveniste, M. Tence, P. Varenne, J. Bideault, C. Boulet, J. Polonsky. Semi-synthèse et structure proposée du facteur activant les plaquettes (PAF): PAF-acéther, un éther analogue de la lysophosphatidylcholine. *C. R. Hebd. Séances Acad. Sci., Ser.D* **1979**, 289, 1037-1040.
- [15] C. Demopoulos, R. Pinchard, D. Hanahan. Platelet activating factor: evidence for 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). *J. Bio. Chem.* **1979**, 254, 9255-9358.
- [16] E. Oberdisse, E. Hackenthal, K. Kuschinsky. *Pharmakologie und Toxikologie* Springer Verlag **1997**, 507-511.
- [17] L.W. Tjoelker, D.M. Stafforini. Platelet-activating factor acetylhydrolases in health and disease. *Biochem Biophys Acta* **2000**, 1488, 102-23.

- [18] Matsuzawa A, Hattori K, Aoki J, Arai H, Inoue K. Protection against oxidative stress-induced cell death by intracellular platelet-activating factor- acetylhydrolase II. *J Biol Chem* **1997**, 272,32315-20.
- [19] Marques M, Pei Y, Southall MD, et al. Identification of platelet-activating factor acetylhydrolase II in human skin. *J Invest Dermatol* **2002**, 119,913-9.
- [20] Dupre DJ, Chen Z, Le Gouill C, et al. Trafficking, ubiquitination, and down-regulation of the human platelet-activating factor receptor. *J Biol Chem* **2003**, 278, 48228-35.
- [21] S. Ishii, T. Shimizu. Platelet-Activating Factor Receptor and genetically engineered PAF receptor mutant mice. *Prog. Lipid Res.* **2000**, 39, 41-82.
- [22] J.B.Travers, J. Huff, M. Rola-Pleszcynski, E. Gelfand, J. Morelli, R. Murphy. Identification of Functional Platelet-Activating Factor Receptors on Human Keratinocytes. *J. Invest. Dermatol.* **1995**, 105, 816-823.
- [23] S. Sato, K. Kume, C. Ito, S. Ishii, T. Shimizu. Accelerated proliferation of epidermal keratinocytes by the transgenic expression of the platelet-activating factor receptor. *Arch. Dermatol. Res.* **1999**, 291, 614-621.
- [24] A. Shimada, Y Ota, Y. Sugiyama, S.Sato, K. Kume, T. Shimizu, S. Inoue. In situ Expression of Platelet-Activating Factor (PAF)-Receptor Gene in Rat Skin and Effects of PAF on Proliferation and Differentiation of Cultured Human Keratinocytes *J.Invest.Dermatol.***1998**, 110, 889-893.
- [25] S. Izaki, T. Yamamoto, Y. Goto, S. Ishimaru, F. Yodate, K. Kitamura, M. Matsuzaki. Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. *Br. J. Dermatol.* **1996**, 134, 1060-1064.
- [26] C. Alappatt, C. Johnson, K. Clay, J. B. Travers. Acute keratinocyte damage stimulates platelet-activating factor production *Arch. Dermatol. Res* **2000**, 292, 256-259.
- [27] H. Brachwitz, C. Vollgraf. Analogs of Alkylphospholipids: Chemistry Effects on the Molecular Level and their Consequences for Normal and malignant cells. *Pharmacol. Ther.* **1995**, 66, 39-82.
- [28] G. Arthur, R. Bittman. The inhibition of cell signaling pathway by antitumor ether lipids. *Biochem. Biophys. Ada* **1998**, 1390, 85-102.
- [29] W. E. Berdel. Membrane- interactive lipids as experimental anticancer drugs. *Br. J. Cancer* **1991**, 64, 208-211.
- [30] D. Berkovic, E. A. Fleer, et al. Effects of hexadecylphosphocholine on cellular function. *Prog Exp Tumor Res.***1992**, 34, 59-68.
- [31] C. Unger, E. Damenz, E. A. M. Fleer, DJ Kim, A. Breiser, P. Hilgard, J. Engel, G. Nagel, H. Eibl. Hexadecylphosphocholine, a new type ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. *Acto Oncol* **1998**, 28, 213-217.
- [32] P. Hilgard. New pharmaceuticals: miltefosine. *Anticancer Drugs* **1990**, 1, 185.
- [33] C. Unger, E. A. Fleer, et al. Antitumoral activity of alkylphosphocholines and analogues in human leukemia cell lines. *Prog Exp Tumor Res* **1992**, 34, 25-32.
- [34] C. Unger, H. Eibl. Drug development from phospholipids. *Onkologie*, **2001**, 24, 18-23.
- [35] P. Hilgard, T. Klenner, J. Stekar, C. Unger. Alkylphosphocholines: A new class of membrane- Active agents. *Cancer Chemother Pharmacol* **1994**, 34, 293-398.

- [36] R. Voegeli, P. Hilgard, J. Arny, C. Unger. An animal model for the treatment of cutaneous tumor lesions; H.H. In Fiebig, D.P. Berger. Immunodeficient mice in oncology. International Symposium Freiburg, November 1990
Contrib Oncol. **1992**, 42, 453-456.
- [37] C. Muschiol, M.R. Berger, B. Schuler, H.R. Scherf, F.T. Garzon, W.J. Zeller, C. Unger, H. Eibl, D. Schmähl. Alkylphosphocholines: Toxicity and anticancer properties.
Lipids. **1987**, 22, 930-934.
- [38] P. Hilgard, J. Stekar, R. Voegeli, J. Engel, W. Schumacher, H. Eibl, C. Unger, M. R. Berger. Characterization of the antitumor activity of hexadecylphosphocholine.
Eur J Clin Onocl **1988**, 24, 1457-1467.
- [39] W.J. Houlihan, M. Lohmeyer, P. Workman, S.H. Cheon.. Phospholipid antitumor agents.*Med. Res. Rev.* **1995**, 15, 157-223.
- [40] E.A.M. Fleer, D. Berkovic, C. Unger, H. Eibl. Phospholipid antitumor agents.
Prog. Exp. Tumor Res. **1992**, 34, 33-46.
- [41] E.E. Kelly, E.J. Modest, C.P. Burns, Unidirectional membrane uptake of the ether lipid antineoplastic agent edelfosine by L1210 cells. *Biochem. Pharmacol.* **1993**, 45, 2435-2439.
- [42] W.E. Berdel. Membrane-interactive lipids as experimental anticancer drugs. *Br. J. Cancer.* **1991**, 64, 208-211.
- [43] F. Mollinedo, C. Gajate, M. Modolell. The ether lipid 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine induces expression of fos and jun proto-oncogenes and activates AP-1 transcription factor in human leukaemic cells.
Biochem. J. **1994**, 302, 325-329.
- [44] A.D. Albani, D.F. Condorelli, G. Mudo, C. Amico, M. Bindoni, N. Belluardo. Platelet-activating factor and its methoxy-analogue ET-18-OCH₃ stimulate immediate early gene expression in rat astroglial cultures.
Neurochem. Int. **1993**, 22, 567-574.
- [45] R. Haase, T. Wieder, C. C. Geilen, W. Reutter. The phospholipid analogue hexadecylphosphocholine inhibits phosphatidylcholine biosynthesis in Madin-Darby canine kidney cells. *FEBS Lett.* **1991**, 288, 129-132.
- [46] H. Tronchere, F. Terce, M. Record, G. Ribbes, H. Chap. Modulation of CTP:phosphocholine cytidyltransferase translocation by oleic acid and the antitumoral alkylphospholipid in HL-60 cells. *Biochem. Biophys. Res. Commun.* **1991**, 176, 157-165.
- [48] Y. Wang, T. D. Sweitzer, P. A. Weinhold, C. Kent Nuclear localization of soluble CTP:phosphocholine cytidyltransferase. *J. Biol. Chem.* **1993**, 268, 5899-5904.
- [49] Y. Wang, J. I. S. MacDonald, C. Kent Regulation of CTP:phosphocholine cytidyltransferase in HeLa cells. Effect of oleate on phosphorylation and intracellular localization. *J. Biol. Chem.* **1993**, 268, 5512-5518.
- [50] M. Mickleit, T. Wieder, K. Buchner, C. Geilen, J. Mulzer and W. Reutter. Glc-PC, a New Type of Glucosidic Phospholipid. *Angew. Chem. Int. Ed. Engl.* **1995**, 34, 2667-2669.
- [51] G. Powis, M.J. Seewald, C. Gratas, D. Melder, J. Riebow, E. J. Modest. Selective inhibition of phosphatidylinositol phospholipase C by cytotoxic ether lipid analogues. *Cancer Res.* **1992**, 52, 2835-2840.

- [52] T. Wieder, Z. Zhang, C. C. Geilen, C.E. Orfanos, A.E. Giuliano, M.C. Cabot. The antitumor phospholipid analog, hexadecylphosphocholine, activates cellular phospholipase D. *Cancer Lett.* 1996, 100, 71-79.
- [53] M. Mickleit, T. Wieder, M. Arnold, C. Geilen, J. Mulzer and W. Reutter. A Glucose-Containing Ether Lipid (Glc-PAF) as an Antiproliferative Analogue of the Platelet- Activating Factor. *Angw. Chem. Int. Ed.* **1998**, 37, 351-353.
- [54] G. Bazill, T. Dexter. Role of endocytosis in the action of ether lipids on WEHI-3B, HL-60 and FDCP-mix A4 cells. *Cancer Res.* **1990**, 50, 7505-7512.
- [55] E. Heesbeen, L. Verdonck, M. Haagsmans, H. van Heugten, G. Staal, G. Rijksen. Adsorption and uptake of the alkyllysophospholipid ET-18-OCH₃ by HL-60 cells during induction of differentiation by dimethylsulfoxide. *Leuk. Res.* **1993**, 17, 143-148.
- [56] C. Gajate, A. Santos-Beneit, A. Macho, M. Lazaro, A. Hernandez-de Rojas, M. Modolell, E. Munoz, F. Mollinedo. Involvement of Mitochondria and Caspase-3 in ET-18-OCH₃- induced Apoptosis of Human Leukemic Cells. *Int. J. Cancer* **2000**, 86, 208-218.
- [57] G. Roos, W. E. Berdel. Sensitivity of human hematopoietic cell lines to an alkyllysophospholipid-derivate. *Leuk. Res.* **1986**, 10, 195-202.
- [58] P. Principe, C. Sidoti. Tumor cell kinetics following antineoplastic ether phospholipid treatment. *Cancer Res.* **1993**, 52, 2509-2515.
- [59] P. Hilgard, E. Kampher, et al. Investigation into the immunological effects of miltefosine, a new anticancer agent under development. *J Cancer Res Clin Oncol.* **1991**, 117, 403-408.
- [60] Y. Honma, T. Kasukabe, et al. Induction of differentiation of cultured human and mouse myeloid leukaemia cells by alkyl-lysophospholipids. *Cancer Res.* **1981**, 41, 3211-3216.
- [61] X. Zhou, X. Lu, C. Richard, W. Xiong, D. Litchfield, R. Bittman, G. Arthur. 1-O-octadecyl-2-O-methyl-glycerophosphocholine inhibits the transduction of growth signals via the MAPK cascade in cultured MCF-7 cells. *J. Clin. Invest.* **1996**, 98, 937-944.
- [62] E. C. Heesbeen, L. F. Verdonck, et al. Alkylphospholipid ET-18-OCH₃ acts as an activator of protein kinase C in HL-60 cells. *FEBS Lett.* **1991**, 290, 231-234.
- [63] D. M. Helfman, K.C. Barnes, et al. Phospholipid-sensitive Ca²⁺-dependent protein phosphorylation system in various types of leukemic cells from human patients and in human leukemic cell lines HL60 and K 562, and its inhibition by alkyllysophospholipid. *Cancer Res.* **1983**, 43, 2955-2961.
- [64] R. M. Epand and D. S. Lester. The role of membrane biophysical properties in the regulation of protein kinase C activity. *Trends Pharmacol. Sci.* **1990**, 11, 317-20.
- [65] J. W. van Blitterswijk, R. L. van der Bend, et al. A metabolite of an antineoplastic ether phospholipid may inhibit transmembrane signalling via protein kinase C. *Lipids*, **1987**, 22, 842-846.
- [66] N. Grosman. Ether lipid (AMG) exhibits both synergistic and inhibitory interactions with the ionophore A23187 in mast cell histamine release. *Immunopharmacology*, **1990**, 19, 113-119.
- [67] H. Salari, P. Dryden, et al. Inhibition of protein kinase C by ether-linked lipids is not correlated with their antineoplastic activity on WEHI-3B and R6X-B15 cells. *Biochem. Biophys. Acta*, **1992**, 1134, 81-88.

- [68] C. Schultz, C. Dinkel. Phosphatidylinosite: Informationsträger der anderen Art. *Nachr. Chem.* **2002**, 50, 590-595.
- [69] M. Berggren, A. Gallegos, L. Dressler, E. Modest, G. Powis. Inhibition of the signalling enzyme phosphatidylinositol-3-kinase by antitumor ether lipid analogues. *Cancer Res.* **1993**, 53, 4297-4302.
- [70] J. Palmblad, J. Samuelsson, et al. Interactions between alkylglycerols and human neutrophil granulocytes. *Scand. J. Clin. Lab. Invest.* **1990**, 50, 363-370.
- [71] M. Lohmeyer, P. Workman. Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vivo anti-tumor activity of the lipids. *Br. J. Cancer.* **1995**, 72, 277-286.
- [72] N. Inoue, K. Hirata, et al. Lysophosphatidylcholine inhibits bradykinin induced phosphoinositide hydrolysis and calcium transients in cultured bovine aortic endothelial cells. *Circ. Res.* **1992**, 71, 1410-1421.
- [73] J. Bergmann, I. Junghahn, et al. Multiple effects of antitumor alkyllysophospholipid Analogs on the cytosolic free Ca^{2+} concentratin in an normal and breast cancer cell line. *Anticancer Res.* **1994**, 14, 1549-1556.
- [74] C. Geilen, T. Wieder, W. Reutter. Hexadecylphosphocholine inhibits translocation of CTP: choline phosphat cytidyltransferase in Madin-Darby canine kidney cells. *J. Biol. Chem.* **1992**, 367, 6719-6724.
- [75] A. Kuhlencord, T. Maniera, H. Eibl, C. Unger. Hexadecylphosphocholine: Oral Treatment of visceral leishmaniasis in mice. *Antimicrob Agents Chemother* **1992**, 36, 1630-1634.
- [76] S. Sundar, F. Rosenkaimer, M.K. Makharia, A.K. Mandal, A. Voss, P. Hilgard, H. W. Murray. Trial of oral miltefosine for visceral leishmaniasis. *Lancet* **1998**, 352, 1821-1823.
- [77] M. E. van Kuijk-Meuwissen, H. E. Junginger, J. A. Bouwstra. Interactions between liposomes and human skin in vitro, a confocal laser scanning microscopy study. *Biochem Biophys Acta* **1998**, 1371, 31-90.
- [78] C. Santos Maia, W. Mehnert, M. Schaller, H.C. Korting, A. Gysler, A. Haberland, M. Schäfer-Korting. *J. Drug Target* **2002**, 10, 489-95.
- [79] W. Mehnert, K. Mäder. Solid lipid nanoparticles: production, characterization and application, *Adv Drug Deliv Rev* **2001**, 47, 165-96.
- [80] K. Danker, M. Dathe, B. Kleuser, K. Kramer, O. Liesenfeld, W. Mehnert, H. Niehaus, W. Reutter, M. Schäfer-Korting. Innovative Wirkstoffe und Carriersysteme für eine gezielte Arzneimitteltherapie. *BioSpektrum* 3/03 9. Jahrgang.
- [81] Behandlung av psoriasis *Information fran Läkemedelverket* **2006**, 5, 5-11.
- [82] S. Izaki, T. Yamamoto, Y. Goto, S. Ishimaru, F. Yudate, K. Kitamura, M. Matsuzaki. Platelet-activating factor and arachidonic acid metabolites in psoriatic inflammation. *Br. J. Dermatol.* **1996**, 134, 1060-1064.
- [83] M. Judge, R. Barr, A. Mallet, F. Courtney, B. Kobza, M. Greavea. Platelet activating factor (PAF) and lyso-PAF in psoriasis. *Arch. Dermatol. Res.* **1994**, 286, 376-379.

- [84] A. Shimada, y. Ota, Y. Sugiyama, S. Sato, K. Kume, T. Shimizu, S. Inoue. In Situ Expression of Platelet- Activating- Factor (PAF)-Receptor Gene in Rat Skin and Effects of PAF on Proliferation and Differentiation of Cultured Human Keratinocytes. *J. Invest. Dermatol.* **1998**, 110, 889-893.
- [85] D. Vossmeier, W. Hofmann, K. Löster, W. Reutter, K. Danker. Phospholipase C γ binds $\alpha_1\beta_1$ Integrin and modulates $\alpha_1\beta_1$ Integrin-specific Adhesion. *J. Biol. Chem.* **2002**, 277, 4636-4643.
- [86] C. J. Sherr, J. M. Roberts. CDK inhibitors: positive and negative regulators of G1-phase progression. *Genes Dev* **1999**, 13, 1501-1512.
- [87] T. Hunt. Cyclins and their partners: from a simple idea to complicated reality. *Semin Cell Biol* **1991**, 2, 213-222.
- [88] M. Hengstschlager, K. Braun, T. Soucek, A. Miloloza, E. Hengstschlager-Ottndad, Cyclin-dependent kinases at the G1-S transition of the mammalian cell cycle. *Mutat Res.* **1999**, 436, 1-9.
- [89] A. Li, J. J Blow. The origin of CDK regulation, *Nat Cell Biol.* **2001**. 3, 182-184.
- [90] D. G. Johnson, C. L. Walker. Cyclins and cell cycle checkpoints, *Annu Rev Pharmacol Toxicol.* **1999**, 39, 295-312.
- [91] J. O. Funk. Cancer cell cycle control. *Anticancer Res* **1999**, 19, 4772-4780.
- [92] M. M. Kasten, A. Giordano. pRb and the cdks in apoptosis and the cell cycle. *Cell Death Differ.* **1998**, 5, 132-140.
- [93] K. L. King, J. A Cidlowski. Cell cycle regulation and apoptosis. *Annu Rev Physiol.* **1998**, 60, 601-617.
- [94] M. V. Blagosklonny. A node between proliferation, apoptosis, and growth arrest. *Bioessays* . **1999**, 21, 704-709.
- [95] M. Guo, B. A Hay. Cell proliferation and apoptosis. *Curr Opin Cell Biol.* **1999**, 11, 745-752.
- [96] B. Pucci, M. Kasten, A. Giordano. Cell cycle and apoptosis. *Neoplasia* .**2000**, 2, 291-299.
- [97] J. Bartkova, J. Lukas, J. Bartek. Aberrations of the G1- and G1/S- regulating genes in human cancer. *Prog Cell Cycle Res* . **1997**, 3, 211-220.
- [98] R. Donnellan, R. Chetty. Cyclin D1 and human neoplasia, *Mol Pathol* .**1998**, 51, 1-7.
- [99] S. V. Ekholm, S. I. Reed. Regulation of G(1) cyclin-dependent kinases in the mammalian cell cycle, *Current Opinion in Cell Biol.* **2000**, 12, 676-684.
- [100] A. Vidal, A. Koff. Cell-cycle inhibitors: three families united by a common cause. *Gene.* **2000**, 247, 1-15.
- [101] L. R. Bernstein, L.A. Liotta. Molecular Mediators of Interactions with Extracellular Matrix Components in Metastasis and Angiogenesis. *Current Opinion in Oncology.* **1994**, 6, 106-113.
- [102] N. Sewald, Mit Integrinen zu neuen Therapien. *Nachr. Chem.* **2002**, 50, 449-453.
- [103] M. Shimaoka; J. Takagi, T. Springer. Conformational Regulation Of Integrin Structure and Function. *Annu. Rev. Biophys. Biomol. Struct.* **2002**, 31, 485-516.

- [104] T. Wieder, W. Reutter, C. Geilen, E. Orfanos, C. Geilen. Mechanism of action of phospholipid analogs as anticancer compounds. *Prog. in Lip. Research*, 1999, 38, 249-259.
- [105] E. Stevens, J. Lowe. Histologie, VHC Verlagsgesellschaft **1992**.
- [106] E. Müller. Wundheilung am Beispiel der Haut *EM* **2003**.
- [107] R.Fahreus, D.P.Lane. The p16 (INK4a) Tumour suppressor protein inhibits alpha5 – beta3 integrin – mediated cell spreading on vitronectin by blocking PKC – dependent localization of alpha5 – beta3 to focal contacts. *EMBO J* 18: 2106 – 2118.
- [108] M. Falasca, S. K. Logan, V. P. Letho, G. Baccante, M. A. Lemmon und J. Schlessinger. Activation of phospholipase C gamma by PI3 Kinase induced PH domain mediated membrane targeting. *Embo J*, **1998**, 17, 414-422.
- [109] K. Burridge, M. Chrzanowska-wodnicka und C. Zhong. Focal adhesion assembly. *Trends in Cell Biology*, **1997**, 7, 342-347.
- [110] A. Fischer, Institut für Molekularbiologie und Biochemie, Freie Universität Berlin, Ag Prof. W. Reutter, unveröffentlichte Ergebnisse
- [111] P. Geer, van der, T.Hunter, R.A. Lindberg, Receptor protein-tyrosine kinases and their signal transduction pathways. *Annu. Rev. Cell. Biol.* **1994**, 10, 251-337.
- [112] G. Carpenter, S.Cohen. Epidermal growth factor. *Annu. Rev. Biochem.* **1979**, 48, 193-216.
- [113] G. Carpenter. Receptor for epidermal growth factor and other polypeptide mitogens. *Annu. Rev. Biochem.* **1987**, 56, 881-914.
- [114] K. Takahashi, K. Suzuki, Y. Tsukatan. Induction of tyrosine Phosphorylation and association of beta-catenin with EGF receptor upon Tryptic digestion of quiescent cells at confluence. *Oncogene*. **1997**, 15, 71-78.
- [115] I. Yamanaka, M Koizumi, T. Baba, S.Yamashita, T. Suzuki, R.Kudo. Epidermal growth factor increased the expression of $\alpha 2\beta 1$ - Integrin and modulated integrin-mediated signalling in human cervical adenocarcinoma cells. *Experimental Cell Research*. **2003**, 286, 165-174.
- [115] K. Danker, B. Gabriel, C. Heidrich, W. Reutter. Focal Adhesion Kinase pp125^{FAK} and $\beta 1$ Integrin Subunit are Constitutively Complexed in HaCaT- Cells. *Exp. Cell. Res.* **1998**, 239, 326-331.
- [116] W. Li, C. Nadelman, N. Gratch, M. Chen, N. Kasahara, D. Woodley. Important Role for Protein Kinase C- δ in Human Keratinocyte Migration on Dermal Collagen. *Exp. Cell. Res.* **2002**, 273, 219-228.
- [117] A. Fischer. Dissertation. Charité-Berlin **2006**.
- [118] T. Bartolmäs. Dissertation, FU-Berlin **2003**.
- [119] E.Fleer, D. Berkovic. Cellular uptake and metabolic fate of hexadecylphosphocholine. *Prog. Exp. Tumor Res.* **1992**, 34, 33-46.
- [120] A. Leroy, G.K. de Bruyne. Alkylphospholipids reversibly open epithelial tight junctions. *Anticancer Res.* **2003**, 23, 27-32.
- [121] T. Wieder, C. E. Orfanos, et.al. Induction of ceramide-mediated apoptosis by anticancer phospholipid analog, Hexadecylphosphocholine. *J. Biol. Chem.* **1998**, 273, 11025-31.

- [123] C. S. Hill, J. Wynne, R. Treisman. The RhoA family GTPases RhoA, Rac1 and CDC42Hs regulate transcriptional activation by SRF
Cell. **1995**, 81, 1159-1170.
- [124] C. V. Carman, T. A. Springer. Integrin avidity regulation: are changes in affinity and conformation underemphasized? *Cur. Opin. Cell. Biol.* **2003**, 15, 547-56.
- [125] M. J. Humphries. Integrin activation: the link between ligand binding and signal transduction. *Curr. Opin. Cell. Biol.* **1996**, 8, 632-640
- [126] G. Bazzoni, M. E. Hemler. Are changes in integrin affinity and conformation overemphasized ?
Trends Biochem. Sci, **1998**, 23, 30-40.
- [127] B. Gabriel, Dissertation, FU-Berlin **1999**.
- [128] A. Fischer, W. Reutter, K. Danker. The ether lipid inositol-C2-PAF is a potent inhibitor of cell proliferation in HaCaT-cells.
Chembiochem. **2006**, 7, 441-447.
- [129] M. C. Gutjahr, J. Rossy, et. al. Role of Rho, Rac and Rho-Kinase in phosphorylation of myosin light chain, development of polarity, and spontaneous migration of Walker 256 carcinoma cells.
Exp. Cell. Res. **2005**, 308, 422-438.
- [130] T. Olmelchenko, J. M. Vasiliev, et. al. Rho-dependent formation of epithelial leader cells during wound healing.
Proc. Natl. Acad. Sci. USA. **2003**, 100, 10788-10793.
- [131] J. Dowling, Q. C. Yu, et. al. Beta4 integrins is required for hemidesmosome formation, cell adhesion and cell survival.
J Cell Biol. **1996**, 134, 559-572.
- [132] A. M. Mercurio, I Rabinovitz, et. al. The alpha 9 beta 4 integrin and epithelial cell migration. *Curr. Opin. Cell. Bio.* **2001**, 13, 541-545.
- [133] R. A. Kinloch, J. Treherne, L. Furness, I. Hajimohamadreza. The pharmacology of apoptosis. *TiPS*, **1999**, 20, 35-42.